SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Mutation C182A

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

There is one clinical trial.

Clinical Trials


1 A Phase 1, Open-Label Study Evaluating the Safety, Tolerability and Efficacy of LCAR-C182A, an Anti-Claudin18.2 CAR-T Cell Therapy in Patients With Advanced Gastric Cancer and Pancreatic Ductal Adenocarcinoma

This is an open label, single center, single arm phase 1 study to evaluate the safety , tolerability, pharmacokinetics and efficacy and immunogenicity of LCAR-C182A cells targeting Claudin18.2 in the treatment of patients with advanced gastric cancer and Pancreatic Ductal Adenocarcinoma.

NCT03890198 Gastric Cancer Pancreatic Ductal Adenocarcinoma Biological: LCAR-C182A cells
MeSH: Adenocarcinoma Stomach Neoplasms
HPO: Neoplasm of the stomach

A Phase 1, Open-Label Study Evaluating the Safety, Tolerability and Efficacy of LCAR-C182A, an Anti-Claudin18.2 --- C182A ---

A Phase 1 Study of LCAR-C182A Cells in the Treatment of Advanced Gastric Cancer and Pancreatic Ductal Adenocarcinoma This is an open label, single center, single arm phase 1 study to evaluate the safety , tolerability, pharmacokinetics and efficacy and immunogenicity of LCAR-C182A cells targeting Claudin18.2 in the treatment of patients with advanced gastric cancer and Pancreatic Ductal Adenocarcinoma. --- C182A ---

A Phase 1 Study of LCAR-C182A Cells in the Treatment of Advanced Gastric Cancer and Pancreatic Ductal Adenocarcinoma This is an open label, single center, single arm phase 1 study to evaluate the safety , tolerability, pharmacokinetics and efficacy and immunogenicity of LCAR-C182A cells targeting Claudin18.2 in the treatment of patients with advanced gastric cancer and Pancreatic Ductal Adenocarcinoma. --- C182A --- --- C182A ---

Transgene Levels of LCAR-C182A CAR-T Cells. --- C182A ---

Transgene Levels of LCAR-C182A CAR-T Cells using sensitive assay methods will be assessed. --- C182A ---

Primary Outcomes

Description: An adverse event is any untoward medical event that occurs in a participant administered an investigational product,and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.

Measure: Number of Participants With Adverse Events

Time: 90 days post infusion

Description: Maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D)

Measure: MTD)/ RP2D regimen finding

Time: 90 days post infusion

Description: Transgene Levels of LCAR-C182A CAR-T Cells using sensitive assay methods will be assessed

Measure: Transgene Levels of LCAR-C182A CAR-T Cells

Time: 2 years post infusion

Description: Venous blood samples will be collected for measurement of CAR-T positive cellular concentration

Measure: Chimeric Antigen Receptor T (CAR-T) Positive Cell Concentration

Time: 2 years post infusion

Description: Serum cytokine concentrations such as IL-2, IL-6, IL-8, 1L-10, TNF-α, IFN-γ will be measured for biomarker assessment

Measure: Systemic Cytokine Concentrations

Time: 2 years post infusion

Secondary Outcomes

Description: The ORR is defined as the proportion of patients with complete or partial response according to Response Evaluation Criteria In Solid Tumors(RECIST) criteria.

Measure: Overall response rate (ORR) after administration

Time: 2 years post infusion

Description: The DOR is defined as the time between the initial onset of complete or partial remission and the onset of disease progression in patients with objective remission according to Response Evaluation Criteria In Solid Tumors(RECIST) criteria.

Measure: Duration of remission (DOR) after administration

Time: 2 years post infusion

Description: The PFS is defined as the Time from enrollment until disease progression or death according to Response Evaluation Criteria In Solid Tumors(RECIST) criteria.

Measure: Progress Free Survival (PFS) after administration

Time: 2 years post infusion

Description: The OS is defined as Time from enrollment until death from any cause according to Response Evaluation Criteria In Solid Tumors(RECIST) criteria.

Measure: Overall Survival (OS) after administration

Time: 2 years post infusion


HPO Nodes


Neoplasm of the stomach
Genes 75
CASP10 IL1B SMAD4 KIT IL1RN TRIP13 MGMT SMAD4 FLCN AKT1 BCL10 SUFU MSH6 APC SDHC NRAS CDKN2B BUB1B SRC BUB1 ACD APC KLF6 APC MSH3 STK11 SDHB APC BUB3 DCC KRAS KIT MSH2 TP53 SEMA4A BAP1 PDGFRA CTNNB1 MITF MSH3 BMPR1A BUB1 DLC1 PIK3CA FGFR3 BMPR1A IRF1 MUTYH PTCH2 SDHA BMPR1A CDK4 CDKN2A EP300 BUB1B ENG FGFR2 AXIN2 TREX1 TERF2IP MC1R ERBB2 CEP57 RPS20 PTPRJ PRKAR1A PIK3CA POT1 PTCH1 CHEK2 TERT APC MLH1 CDH1 APC